Table 1:
Participant Demographics
| Raltegravir (n=10) | Dolutegravir (n=10) | P-value | ||
|---|---|---|---|---|
| Age (years) | 55 (48–64) | 50 (32–56) | 0.03 | |
| Male | 6 (60%) | 9 (90%) | 0.30 | |
| Race | ||||
| Caucasian | 3 | 3 | ||
| BMI | 30.7 (18.7–41.4) | 28.9 (21.0–35.6) | 0.67 | |
| Time Since HIV Diagnosis (years) | 9.5 (4.0–22.0) | 17.0 (1.0–24.0) | 0.62 | |
| Time on study drug (years) | 5.4 (2.3–6.7) | 1.0 (0.1–1.5) | < 0.001 | |
| Current CD4+ | 812 (594–956) | 620 (223–1300) | 0.32 | |
| CD4+ nadir (cells/mm3) | 356 (9.–476) | 74 (2–458) | 0.18 | |
| Peak HIV RNA (copies/mL) | 30580 (137–298700) | 47427 (463–650200) | 0.91 | |
Data are reported as median (min-max). BMI = body mass index.